Irregular eating patterns sometimes develop when appetite is significantly reduced
The body then produces more insulin to compensate
GLP-3 (Reta) 20mg GLP-3 (Retatrutide) is a multi-pathway receptor agonist widely utilized in preclinical research involving metabolic regulation, incretin signaling, glucagon-associated pathways, and energy balance-related biochemical processes
As of 2024, retatrutide has not received MHRA or EMA marketing authorisation and is not listed in the BNF
GLP-1 patches don't contain any GLP-1, they haven't been clinically approved, and there's no strong evidence that they lead to meaningful weight loss
As part of this, I had them prep easy, grab-and-go options